• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.阿基仑赛（axicabtagene ciloleucel）治疗成人Richter综合征患者的临床活性
Blood Adv. 2020 Oct 13;4(19):4648-4652. doi: 10.1182/bloodadvances.2020002783.
2
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
3
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.嵌合抗原受体 T 细胞疗法 Axicabtagene Ciloleucel 治疗大 B 细胞淋巴瘤的研发与应用：综述。
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
4
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.阿基仑赛注射液用于既往接受过不同的靶向CD19嵌合抗原受体T细胞疗法治疗的复发或难治性淋巴瘤。
Blood Adv. 2020 Oct 13;4(19):4869-4872. doi: 10.1182/bloodadvances.2020002292.
5
Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.axi-cel（阿基仑赛）治疗复发难治性弥漫性大B细胞淋巴瘤后的迟发性神经毒性
Bone Marrow Transplant. 2021 Mar;56(3):683-685. doi: 10.1038/s41409-020-01029-4. Epub 2020 Aug 11.
6
Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.阿基仑赛注射液用于老年城市间人群复发/难治性大B细胞淋巴瘤的安全性
Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. doi: 10.1038/s41409-021-01280-3. Epub 2021 Apr 12.
7
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.接受axi-cabtagene ciloleucel治疗后病情进展的大B细胞淋巴瘤患者的预后
Blood. 2021 Apr 1;137(13):1832-1835. doi: 10.1182/blood.2020006245.
8
Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.阿基仑赛嵌合抗原受体T细胞疗法治疗继发中枢神经系统受累的淋巴瘤
Mayo Clin Proc. 2019 Nov;94(11):2361-2364. doi: 10.1016/j.mayocp.2019.09.006.
9
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.阿基仑赛注射液，一种用于侵袭性非霍奇金淋巴瘤的一流嵌合抗原受体T细胞疗法。
Leuk Lymphoma. 2018 Aug;59(8):1785-1796. doi: 10.1080/10428194.2017.1387905. Epub 2017 Oct 23.
10
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 研究中高龄患者的结局，该研究为 axicabtagene ciloleucel 治疗难治性大 B 细胞淋巴瘤的关键研究。
Blood. 2020 Jun 4;135(23):2106-2109. doi: 10.1182/blood.2019004162.

引用本文的文献

1
Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation.嵌合抗原受体（CAR）-T细胞疗法治疗里氏转化。
Front Oncol. 2025 Jun 9;15:1591360. doi: 10.3389/fonc.2025.1591360. eCollection 2025.
2
The importance of status in cancer therapy: The example of chronic lymphocytic leukemia.状态在癌症治疗中的重要性：以慢性淋巴细胞白血病为例。
Mol Biol Res Commun. 2025;14(3):179-198. doi: 10.22099/mbrc.2025.51477.2054.
3
Updates on the Treatment of Richter's Syndrome, Including Novel Combination Approaches.里氏综合征的治疗进展，包括新型联合治疗方法
Cancers (Basel). 2025 Mar 11;17(6):943. doi: 10.3390/cancers17060943.
4
Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review.克隆相关性作为慢性淋巴细胞白血病Richter转化的预后标志物：一项系统综述
Blood Adv. 2025 Jun 10;9(11):2773-2780. doi: 10.1182/bloodadvances.2024015594.
5
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphoma.抗 CD19 嵌合抗原受体 T 细胞疗法在 Richter 转化型淋巴瘤中的疗效不如在初发弥漫性大 B 细胞淋巴瘤和转化性低级别 B 细胞淋巴瘤中。
Haematologica. 2024 Nov 1;109(11):3566-3577. doi: 10.3324/haematol.2023.284664.
6
CAR-T Cells in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中的嵌合抗原受体T细胞
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024045. doi: 10.4084/MJHID.2024.045. eCollection 2024.
7
Treatment of Richter's Transformation with Novel Therapies.新型疗法治疗里希特转化。
Curr Hematol Malig Rep. 2024 Apr;19(2):45-55. doi: 10.1007/s11899-023-00721-8. Epub 2024 Jan 9.
8
Richter transformation-is there light at the end of this tunnel?Richter转化——这条隧道尽头有曙光吗？
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):427-432. doi: 10.1182/hematology.2023000442.
9
Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?慢性淋巴细胞白血病的 Richter 转化——我们是否取得了进展？
Curr Hematol Malig Rep. 2023 Oct;18(5):144-157. doi: 10.1007/s11899-023-00701-y. Epub 2023 Jun 9.
10
CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?中枢神经系统血液疾病中CAR T细胞相关神经毒性：它仍然是一个需要关注的问题吗？
Front Neurol. 2023 Apr 6;14:1144414. doi: 10.3389/fneur.2023.1144414. eCollection 2023.

本文引用的文献

1
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.伊布替尼治疗失败后靶向 CD19 的嵌合抗原受体 T 细胞与伊布替尼联合治疗慢性淋巴细胞白血病的可行性和疗效。
Blood. 2020 May 7;135(19):1650-1660. doi: 10.1182/blood.2019002936.
2
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.抗 CD19 嵌合抗原受体 T 细胞疗法 Lisocabtagene Maraleucel 联合伊布替尼或阿卡替尼的抗肿瘤活性。
J Immunother. 2020 May;43(4):107-120. doi: 10.1097/CJI.0000000000000307.
3
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy.慢性淋巴细胞白血病细胞损害 CD8 T 细胞中的线粒体功能，从而阻碍嵌合抗原受体 T 细胞疗法的疗效。
Blood. 2019 Jul 4;134(1):44-58. doi: 10.1182/blood.2018885863. Epub 2019 May 10.
4
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
5
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
6
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.慢性淋巴细胞白血病中 CD19 嵌合抗原受体 (CAR) T 细胞治疗应答和耐药的决定因素。
Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.
7
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
8
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.一项针对里氏综合征一线R-EPOCH化疗免疫疗法的单机构回顾性队列研究表明，复杂慢性淋巴细胞白血病核型是一个不良预后因素。
Br J Haematol. 2018 Jan;180(2):259-266. doi: 10.1111/bjh.15035. Epub 2017 Nov 28.
9
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.依鲁替尼治疗失败后，用CD19特异性嵌合抗原受体修饰的T细胞治疗慢性淋巴细胞白血病的持久分子缓解。
J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.
10
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.伊布替尼可增强嵌合抗原受体T细胞在白血病中的植入及疗效。
Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.

Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.

作者信息

Kittai Adam S, Bond David A, William Basem, Saad Ayman, Penza Sam, Efebera Yvonne, Larkin Karilyn, Wall Sarah A, Choe Hannah K, Bhatnagar Bhavana, Vasu Sumithira, Brammer Jonathan, Shindiapina Polina, Long Meixiao, Mims Alice, O'Donnell Lynn, Bhat Seema A, Rogers Kerry A, Woyach Jennifer A, Byrd John C, Jaglowski Samantha M

机构信息

Division of Hematology, Department of Internal Medicine.

Arthur G. James Comprehensive Cancer Center.

出版信息

Blood Adv. 2020 Oct 13;4(19):4648-4652. doi: 10.1182/bloodadvances.2020002783.

DOI:10.1182/bloodadvances.2020002783
PMID:33002129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7556158/
Abstract
摘要